RATIONALE: In normal and diseased vascular smooth muscle (SM), the RhoA pathway, which is activated by multiple agonists through G protein-coupled receptors (GPCRs), plays a central role in regulating basal tone and peripheral resistance. This occurs through inhibition of myosin light chain phosphatase, leading to increased phosphorylation of the myosin regulatory light chain. Although it is thought that specific agonists and GPCRs may couple to distinct RhoA guanine nucleotide exchange factors (GEFs), thus raising the possibility of selective targeting of specific GEFs for therapeutic use, this notion is largely unexplored for SM contraction. OBJECTIVE: We examine whether p63RhoGEF, known to couple specifically to Gα(q/11) in vitro, is functional in blood vessels as a mediator of RhoA activation and if it is selectively activated by Gα(q/11) coupled agonists. METHODS AND RESULTS: We find that p63RhoGEF is present across SM tissues and demonstrate that silencing of the endogenous p63RhoGEF in mouse portal vein inhibits contractile force induced by endothelin-1 to a greater extent than the predominantly Gα(12/13)-mediated thromboxane analog U46619. This is because endothelin-1 acts on Gα(q/11) as well as Gα(12/13). Introduction of the exogenous isolated pleckstrin-homology (PH) domain of p63RhoGEF (residues 331-580) into permeabilized rabbit portal vein inhibited Ca2+ sensitized force and activation of RhoA, when phenylephrine was used as an agonist. This reinforces the results based on endothelin-1, because phenylephrine is thought to act exclusively through Gα(q/11). CONCLUSION: We demonstrate that p63RhoGEF selectively couples Gα(q/11) but not Gα(12/13), to RhoA activation in blood vessels and cultured cells and thus mediates the physiologically important Ca2+ sensitization of force induced with Gα(q/11)-coupled agonists. Our results suggest that signaling through p63RhoGEF provides a novel mechanism for selective regulation of blood pressure.
RATIONALE: In normal and diseased vascular smooth muscle (SM), the RhoA pathway, which is activated by multiple agonists through G protein-coupled receptors (GPCRs), plays a central role in regulating basal tone and peripheral resistance. This occurs through inhibition of myosin light chain phosphatase, leading to increased phosphorylation of the myosin regulatory light chain. Although it is thought that specific agonists and GPCRs may couple to distinct RhoAguanine nucleotide exchange factors (GEFs), thus raising the possibility of selective targeting of specific GEFs for therapeutic use, this notion is largely unexplored for SM contraction. OBJECTIVE: We examine whether p63RhoGEF, known to couple specifically to Gα(q/11) in vitro, is functional in blood vessels as a mediator of RhoA activation and if it is selectively activated by Gα(q/11) coupled agonists. METHODS AND RESULTS: We find that p63RhoGEF is present across SM tissues and demonstrate that silencing of the endogenous p63RhoGEF in mouse portal vein inhibits contractile force induced by endothelin-1 to a greater extent than the predominantly Gα(12/13)-mediated thromboxane analog U46619. This is because endothelin-1 acts on Gα(q/11) as well as Gα(12/13). Introduction of the exogenous isolated pleckstrin-homology (PH) domain of p63RhoGEF (residues 331-580) into permeabilized rabbit portal vein inhibited Ca2+ sensitized force and activation of RhoA, when phenylephrine was used as an agonist. This reinforces the results based on endothelin-1, because phenylephrine is thought to act exclusively through Gα(q/11). CONCLUSION: We demonstrate that p63RhoGEF selectively couples Gα(q/11) but not Gα(12/13), to RhoA activation in blood vessels and cultured cells and thus mediates the physiologically important Ca2+ sensitization of force induced with Gα(q/11)-coupled agonists. Our results suggest that signaling through p63RhoGEF provides a novel mechanism for selective regulation of blood pressure.
Authors: Christina M Wuertz; Akos Lorincz; Christiane Vettel; Martin A Thomas; Thomas Wieland; Susanne Lutz Journal: FASEB J Date: 2010-08-25 Impact factor: 5.191
Authors: Ronald L Neppl; Lubomir T Lubomirov; Ko Momotani; Gabriele Pfitzer; Masumi Eto; Avril V Somlyo Journal: J Biol Chem Date: 2008-12-17 Impact factor: 5.157
Authors: Angela Wirth; Zoltán Benyó; Martina Lukasova; Barbara Leutgeb; Nina Wettschureck; Stefan Gorbey; Petra Orsy; Béla Horváth; Christiane Maser-Gluth; Erich Greiner; Björn Lemmer; Günther Schütz; J Silvio Gutkind; Stefan Offermanns Journal: Nat Med Date: 2007-12-16 Impact factor: 53.440
Authors: Ehsan Amin; Badri Nath Dubey; Si-Cai Zhang; Lothar Gremer; Radovan Dvorsky; Jens M Moll; Mohamed S Taha; Luitgard Nagel-Steger; Roland P Piekorz; Avril V Somlyo; Mohammad R Ahmadian Journal: Biol Chem Date: 2013-11 Impact factor: 3.915
Authors: Thomas M Leurgans; Maria Bloksgaard; Jonathan R Brewer; Luis A Bagatolli; Maise H Fredgart; Kristoffer Rosenstand; Maria L Hansen; Lars M Rasmussen; Akhmadjon Irmukhamedov; Jo Gr De Mey Journal: Br J Pharmacol Date: 2016-04-06 Impact factor: 8.739
Authors: Patrick Osei-Owusu; Russell H Knutsen; Beth A Kozel; Hans H Dietrich; Kendall J Blumer; Robert P Mecham Journal: Am J Physiol Heart Circ Physiol Date: 2014-01-10 Impact factor: 4.733